You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

 

Online download statistics by month:

Online download statistics by month: August 2021 to July 2025

AbstractFullPdf
Aug 2021598598224
Sep 202137637779
Oct 202119819871
Nov 202111711730
Dec 202111511641
Jan 2022909137
Feb 2022798247
Mar 2022535831
Apr 202211511834
May 2022676937
Jun 2022666722
Jul 2022919220
Aug 2022989928
Sep 202210610624
Oct 2022868626
Nov 2022848627
Dec 2022646419
Jan 2023454523
Feb 2023585919
Mar 2023787936
Apr 2023242417
May 2023292918
Jun 202317177
Jul 2023202123
Aug 2023303012
Sep 2023353520
Oct 2023606028
Nov 2023454519
Dec 2023373737
Jan 2024505130
Feb 2024565635
Mar 2024606043
Apr 2024505030
May 2024646232
Jun 2024555630
Jul 2024787935
Aug 2024555725
Sep 2024484832
Oct 2024636337
Nov 2024646534
Dec 2024757644
Jan 2025555529
Feb 2025444427
Mar 2025333326
Apr 2025686842
May 2025535334
Jun 2025262616
Jul 2025110
Total387939081637